Business Context and Reporting Period
Company: Cactus Ventures, Inc. (now operating as a holding company for Actinium Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 28, 2012
Event: Completion of a reverse takeover (Share Exchange) wherein Cactus Ventures acquired 21% of Actinium Pharmaceuticals, Inc. (API) in exchange for 4,309,015 shares of Cactus common stock. Actinium is the accounting acquirer. The transaction resulted in a change of control, with former Actinium shareholders becoming the controlling shareholders of Cactus. The company is now a clinical-stage biopharmaceutical firm focused on radioimmunotherapy for cancer.
Key Financial Metrics
Revenue: $0 (No commercial revenue generated to date).
Profitability:
- Net Loss (9 months ended Sept 30, 2012): $5,483,954
- Net Loss (Year ended Dec 31, 2011): $3,444,795
- Accumulated Deficit (as of Sept 30, 2012): Approximately $52.8 million
Cash Flow (9 months ended Sept 30, 2012):
- Operating Activities: $(3,795,480) used
- Financing Activities: $660,163 provided
- Cash Balance (Sept 30, 2012): $2,566,669
Recent Capital Raise (Dec 19, 2012):
- Gross Proceeds: $5,151,450
- Net Proceeds: $4,469,776
- Instrument: Sale of Units (Common Stock + Warrants) to accredited investors.
Debt: The company has outstanding 8% Senior Subordinated Unsecured Convertible Promissory Notes. Interest expense for the nine months ended Sept 30, 2012, was $952,241.
Material Changes vs. Prior Period
- Corporate Structure: Transitioned from a "blank check" shell company (Cactus) to a clinical-stage biopharmaceutical company (Actinium) via reverse merger.
- Management: Former Cactus director/officer Diane S. Button resigned. New leadership appointed: Jack V. Talley (CEO), Dragan Cicic (COO/CMO), and Enza Guagenti (CFO).
- Operating Expenses: Significant increase in Research & Development (R&D) expenses ($2.72M vs $0.23M in prior 9-month period) due to the initiation of a multi-center clinical trial for Actimab-A. General and Administrative expenses also rose significantly ($1.52M vs $0.38M) due to professional fees and stock-based compensation related to the public offering.
- Accounting Firm: Dismissed R.R. Hawkins & Associates International and engaged GBH CPAs, PC as the new independent auditor.
Guidance, Outlook, and Risks
Outlook and Capital Needs:
- The company expects to incur net losses for at least the next several years.
- Management estimates cash needs of up to $20,000,000 in 2013 to fund R&D, clinical trials, and working capital.
- First product commercialization is not expected until at least 2016.
Key Risks:
- Liquidity: Substantial doubt exists regarding the ability to continue as a going concern without additional financing.
- Regulatory: No products are approved; success depends on FDA approval of Biologics License Applications (BLA) for Actimab-A and Iomab-B.
- Clinical Trials: Risks include failure to demonstrate efficacy, adverse events (e.g., bone marrow suppression observed in trials), and patient enrollment delays.
- Supply Chain: Dependence on limited supplies of Actinium-225 (Ac-225) from Oak Ridge National Laboratory and the need to scale proprietary manufacturing.
- Intellectual Property: Some key patents for the HuM-195 antibody may expire before commercialization; the BC8 antibody used in Iomab-B is not patent-protected.
Unusual Items: The transaction was accounted for as a reverse recapitalization. The company is subject to "penny stock" regulations due to its OTCBB listing and low share price.
Investor Verification Checklist
- Cash Runway: Verify if the $4.47M net proceeds from the December 2012 offering are sufficient to meet the stated $20M cash need for 2013.
- Clinical Trial Status: Confirm the current enrollment numbers and safety data for the Actimab-A Phase I/II trial and the Iomab-B pivotal trial design.
- Isotope Supply: Validate the terms of the contract with Oak Ridge National Laboratory and the status of the proprietary cyclotron manufacturing capability.
- Related Party Transactions: Review the ongoing agreements and financial support arrangements with Memorial Sloan-Kettering Cancer Center (MSKCC), a significant shareholder.
- Registration Rights: Confirm the timeline for the registration statement required for the resale of shares issued to investors in the recent offering.